C4 Therapeutics, Inc.
CCCCNext catalyst
Data Readout — Cemsidomide
Get an email about CCCC's next catalysts
Track C4 Therapeutics (CCCC) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
No other upcoming event in our data.
1 upcoming, 1 past
Data Readout — Cemsidomide
C4 Therapeutics is preparing for cemsidomide readouts expected in 2027, with the article suggesting the stock is priced for perfect outcomes.
SourceMarket Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Cemsidomide | Phase 2 | Multiple Myeloma | - | - |
Frequently asked questions
What is in C4 Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in C4 Therapeutics, Inc.'s (CCCC) pipeline across Phase 2. Its lead program is Cemsidomide (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is C4 Therapeutics, Inc.'s next FDA catalyst?→
C4 Therapeutics, Inc.'s (CCCC) next tracked catalyst is a data readout expected Jan 1, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CCCC biotech catalysts?→
Add CCCC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow C4 Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.